CARLSBAD, Calif. (AP) _ GenMark Diagnostics Inc. (GNMK) on Wednesday reported a loss of $11.7 million in its third quarter.
The Carlsbad, California-based company said it had a loss of 20 cents per share.
The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share.
The molecular diagnostics company posted revenue of $20.9 million in the period, which topped Street forecasts. Three analysts surveyed by Zacks expected $20.7 million.
GenMark Diagnostics expects full-year revenue in the range of $85 million to $90 million.
GenMark Diagnostics shares have climbed 20% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $5.82, a climb of 32% in the last 12 months.